Fibroblast growth factors (FGF), and in particular FGF8, have been strongly implicated in prostate carcinogenesis. This study investigated the expression of Sef, a key inhibitory regulator of FGF signalling, in prostate cancer. In a panel of cell lines, hSef was detected in both androgen-dependent and independent cells but was significantly reduced in highly metastatic derivative clones. hSef expression was not influenced by androgenic stimulation. Forced downregulation of hSef by siRNA increased FGF8b induced cell migration (P ¼ 0.02) and invasion (P ¼ 0.007). Reduced hSef levels also enhanced FGF8b stimulated expression of MMP9 (P ¼ 0.005). mRNA in situ hybridization revealed hSef expression in 80% (8/10) of benign biopsies but in only 69% (23/33) of Gleason sum 4-7 and 35% (10/28) of Gleason sum 8-10 cancer biopsies (P ¼ 0.004). Quantitative PCR of microdissected glands confirmed this trend (P ¼ 0.001). hSef was expressed in 69% (27/39) of non-metastatic tumours but in only 18% (2/11) of metastatic tumours (P ¼ 0.004, n ¼ 50). hSef expression was next correlated with earlier data on FGF8b expression in a subgroup of cancers. In this cohort, 86% (19/22) of high-grade cancers expressed FGF8 but only 31% (7/22) expressed hSef. Positive FGF8 expression but a loss of hSef was observed in 88% (7/8) of metastatic tumours. In contrast, metastasis was evident in only 10% (1/10) of tumours, which co-expressed both FGF8 and hSef (Po0.001). These results suggest evidence that hSef is downregulated in advanced prostate cancer and might facilitate an enhanced tumorigenic response to FGFs. Further research into the role of hSef in cancer cell signalling and the mechanism of its downregulation may contribute to more effective targeting of growth factors in prostate cancer.
Prostate cancer is the second leading cause of cancer deaths in the western world (Jemal et al., 2004) . Although radical treatments can improve survival for local disease there are few therapeutic options for hormone refractory and metastatic prostate cancer (Johansson et al., 2004) . The fibroblast growth factor (FGF) axis has been closely linked to prostate carcinogenesis and is an important target for therapy (Ozen et al., 2001; Kwabi-Addo et al., 2004; Gowardhan et al., 2005) . We have previously shown evidence that the mitogenic peptide FGF8 is significantly overexpressed in clinical prostate cancer at the mRNA and protein level (Dorkin et al., 1999; Gnanapragasam et al., 2003) . Induced overexpression of FGF8 (isoform b) in vitro and in vivo is capable of enhancing tumour growth, migration, invasion and angiogenesis (Rudra-Ganguly et al., 1998; Song et al., 2000 Song et al., , 2002 Mattila et al., 2001; Ruohola et al., 2001) . Furthermore, FGF receptor (FGFR) expression and splice form characteristics are known to alter in advanced prostate cancer resulting in a more favourable environment for FGF8 binding (Yan et al., 1992; Leung et al., 1996; Gowardhan et al., 2005) .
In recent years, it has become clear that FGF signalling is regulated by endogenous inhibitors that influence the impact of growth factor stimulation. Similar expression to FGF (Sef) was first identified as a gene coexpressed with FGF8 in embryogenesis Lin et al., 2002; Tsang et al., 2002) . Gain and loss of function studies implicate Sef as a feedback-induced inhibitor of FGF signalling Tsang et al., 2002) . The point of Sef action however remains contentious. Sef has been shown to coimmunoprecipitate with the FGFR and inhibit phosphorylation of both FGFR and the receptor substrate FRS2 (Kovalenko et al., 2003) . Other reports have suggested that Sef acts further downstream either at the level of MEK or ERK Yang et al., 2003) . Torii et al. (2004) have proposed that human Sef (hSef) acts as a spatial regulator for ERK signalling and blocks its translocation to the nucleus. These investigators concur however that Sef has a crucial role in modulating FGF signalling. Given its potential importance in FGF signal regulation, the role of Sef in tumorigenesis is of singular interest. Loss of Sef expression might contribute to tumour progression by facilitating aberrant and overactive signalling. In this study, we investigated the role of hSef in prostate cancer. Our primary goal was to determine if the expression and regulatory function of hSef was suppressed in the process of carcinogenesis and if this might enhance the tumorigenic effects of FGFs.
hSef expression was first investigated in a panel of prostate cancer cell lines including derived subclones known to demonstrate increased in vivo invasive and metastatic capability. We observed hSef transcript expression in androgen-dependent LNCaP cells and androgen-independent PC3 cells using semiquantitative PCR. The more metastatic derivative cell lines LN3 and PC3M however expressed significantly lower levels of hSef compared to parental cell lines (LNCaP and PC3, respectively) ( Figure 1a ). DU145 cells (derived from a brain metastasis) expressed very low levels of hSef. We further quantified this finding using real-time PCR (qPCR). We again observed positive hSef expression in androgen-dependent LNCaP cells and androgen-independent PC3 cells. PC3M cells however expressed up to 90% lower levels of hSef compared to parental PC3 cells (Figure 1b ). DU145 cells again expressed barely detectable levels of hSef. In our experiments, hSef expression did not appear to be dependent on the androgen-responsive status of the cell. To test this, LNCaP cells were first deprived of and then stimulated with androgens. Neither treatment altered the endogenous levels of hSef (Figure 1c ). PSA expression in contrast, was induced by up to 20-fold by androgens. We further investigated this using the androgen-sensitive CWR22 prostate xenograft model which has previously been established in our group (Gnanapragasam et al., 2002) . In these experiments neither castration nor testosterone supplementation of tumour-bearing mice altered hSef mRNA levels compared to controls (data Figure 1 hSef transcript expression is reduced in highly metastatic prostate cancer cell lines. (a) RT-PCR with primers for the fulllength coding sequence of human Sef (hSef) was used to study hSef expression in a panel of cell lines. (b) Real-time PCR primers were designed for hSef using Primer Express 2.0 (Applied Biosystems, Warrington, UK) and were as follows: -hSef forward 5 0 -CAGA ACTTCGGCTTCCGTTT-3 0 , reverse 5 0 -CTGCTCACAGGTCTTTCGCTTG-3 0 . Assessment of hSef expression was performed through detection of cDNA amplification using SYBR green and the absolute quantification method (corrected for GAPDH). Results are expressed as the mean of four repeat experiments. (c) LNCaP cells were treated at a dose of 10 nM R1881 (synthetic androgen) before mRNA extraction. cDNA was then assayed by qPCR for hSef and PSA expression. Results shown are the mean of three experiments repeated in triplicate and expressed as a fold increase compared to uninduced cells. PSA and GAPDH primers were designed using primer express. (PSA-Prostate-specific antigen) (d) In knockdown experiments, hSef siRNA sets was synthesized as duplex RNA (Eurogentec, GMBH). Three sets were tested before deciding on the optimum hSef siRNA (Si) sequence: 5 0 -ACAU CACCUUCAAAUAUGAdTdT-3 0 , 5 0 -dTdTUGUAGUGGAAGUUUAUACU-3 0 . Cells were plated and allowed to adhere for 24 h. siRNA oligonucleotides was then transfected with RNAifect (Qiagen, Crawley, UK) according to the manufacturer's instructions. Controls were used in parallel for each siRNA experiment using a non-silencing scrambled oligonucleotide (SC) (Qiagen). The results shown are the composite values of six separate sets of transfections. (e and f) In migration assays, transfected cells were re-plated out into BD Falcont migration chambers in basal medium (BM). Serum-containing medium (FM) was used as the stimulant. Cells were allowed to migrate for 12 h. For invasion assays, transfected cells were plated out into chambers coated with Matrigelt (BD Falcont, Oxford, UK). Cells were allowed to invade for a total of 24 h. Migrated and invasive cells were fixed in methanol for 20 min at À201C, stained with haematoxylin and counted using a bright field microscope at Â 400 magnification. A minimum of four different fields of view were used to obtain an average count per section. Results shown are the mean of three experiments and expressed as a fold increase over uninduced scramble oligonucleotide transfected controls. Statistical analysis was performed using two-tailed Student's T-test. A P-value of less than 0.05 was taken as statistically significant. (*Po0.001, **P ¼ 0.006).
Loss of Sef in prostate cancer S Darby et al not shown). These results suggest that hSef expression is not influenced by androgens or the transition to hormone independence. Downregulation of hSef, however, appears to occur in cells known to demonstrate increased in vivo invasive and metastatic capability (Koslowski et al., 1984; Pettaway et al., 1996) . The phenotypic advantage of low levels of hSef was investigated using small interference RNA (siRNA) in PC3 cells. In the absence of a suitable hSef antibody, the specificity and efficiency of target knockdown was tested using qPCR. Three siRNA oligonucleotide sets were tested before deciding on the optimum construct for efficient hSef knockdown. Transcript expression was routinely downregulated by up to 80% in siRNAtransfected PC3 cells compared to scrambled siRNA controls (Figure 1d ). Using serum containing medium as a stimulus, hSef knockdown in PC3 cells produced a significant increase in cellular migration compared to controls (Po0.001) (Figure 1e ). In matrigel assays, hSef knockdown also significantly increased cellular invasion compared to controls ( Figure 1f ) (P ¼ 0.006). These results raise the possibility that a reduction in endogenous hSef levels facilitates a more invasive phenotype in prostate cancer cells.
We next asked what pathway might be involved in this effect. hSef is known to modulate FGF8 signalling in embryogenesis. In prostate cancer cells, FGF8 is a mitogenic and metastatic stimulus. FGFR4, potently activated by FGF8, is also known to be highly expressed in prostate cancer cell lines (Ornitz et al., 1996; Gowardhan et al., 2005) . We therefore tested if hSef knockdown might enhance the tumorigenic response to FGF8. Migration and invasion assays were repeated in PC3 cells using FGF8 as a stimulus. In scramble transfected controls FGF8 treatment increased cell migration and invasion by twofold. In hSef knockdown cells, however, FGF8 stimulation increased migration and invasion by a further twofold (P ¼ 0.02 and P ¼ 0.007, respectively) (Figure 2a and b) . We next asked what mechanism might be involved. In both hSef knockdown and scramble transfected cells TIMP1, TIMP2, MMP1 and MMP 2 expression was unchanged following FGF8 stimulation. MMP9 expression however was increased by up to fourfold in scramble transfected cells and by up to 10-fold in hSef knockdown cells (P ¼ 0.005, compared to scramble transfected controls) (Figure 2c ). These results are consistent with the findings of Ruohola et al. (2001) who observed MMP9 induction by FGF8 in breast cancer cells. MMP9 induction was blocked by co-treatment with a MEK inhibitor suggesting signalling through the MAPK pathway (Figure 2c ). These results suggest that loss of hSef expression enhances FGF8 induced prostate cancer cell migration and invasion. This effect may be mediated, at least in part, through induction of MMP9 expression, which may facilitate breakdown of the extracellular matrix and tumour cell invasion. We also observed that hSef knockdown increased FGF2 induced Figure 2 hSef knockdown enhances FGF8-stimulated prostate cancer cell migration and invasion. (a) Migration assays were repeated in PC3 cells using FGF8 (isoform b) or FGF2 as a stimulus (100 and 10 ng/ml, respectively; R&D systems, UK) (b) Invasion assays were repeated using FGF8b or FGF2. Results shown are the mean of three experiments and expressed as a fold increase over uninduced scramble oligonucleotide transfected controls. (c) Scramble or hSef siRNA oligonucleotide transfected cells were treated with FGF8b before mRNA extraction and profiling for invasion markers. The MEK inhibitor PD98059 (Calbiochem, Nottingham, UK) was used at a dose of 25 mmol and added to each well 2 h before stimulation. Expression was detected by qPCR as previously described. Results shown are the mean of three separate experiments repeated in triplicate and expressed as a fold increase over uninduced scramble transfected controls. Primers for the invasion markers shown were again designed using Primer Express. (*P ¼ 0.02, **P ¼ 0.01, ***P ¼ 0.007, ****P ¼ 0.005).
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S Darby et al cell migration and invasion (P ¼ 0.01 in both) suggesting that its effects are not confined to the FGF8 axis alone (Figure 2a and b) . hSef expression was next studied in a cohort of 71 prostate biopsies by mRNA in situ hybridization: 10 benign prostates, 51 primary prostate cancers and 10 cases of hormone refractory prostate cancer. Breast tissue was used as a positive control and demonstrated strong hSef expression in ductal carcinoma cells (Figure 3a) . Liver tissue failed to give positive signals consistent with previous reports (Figure 3b) . In all cases signals were only seen with the antisense probe. Sense probes failed to generate signals (data not shown). In prostate tissue, hSef expression was seen primarily in epithelial cells with occasional signals in smooth muscle fibres. Positive hSef expression was detected in 80% (8/10) of benign prostate biopsies and 54% (33/61) of cancer biopsies (Figure 3c-e) . Further analysis of the cancer biopsies revealed that hSef was expressed in 71% (23/32) of Gleason sum 4-7 Signal intensity in prostate sections was scored by two independent observers (VJG, MMK) without prior knowledge of the clinical details. The level of hSef mRNA expression was scored as being either negative (À) or positive ( þ ). Negative hSef expression was defined as no signals or less than 10% positive signals in the glandular epithelial cells. Differences in expression of hSef mRNA in relation to clinical parameters were analysed using the Mann-Whitney test adjusted for ties or the w 2 -test where appropriate. (g) Absolute quantity of hSef in benign and malignant glands obtained by LCM. Prospective consent was obtained from men undergoing transurethral resection of the prostate. Representative tissue chips were collected in isopentane (Sigma) on dry ice. 5 mm cryosections were cut, stained with 1% toluidine blue and washed in RNAse-treated water. Benign or malignant glands were identified and cut using the Leica AS LCM system. Pre-and post-capture images and the pathological grade were reviewed and verified by two observers (100% concordance) before RNA extraction (RNeasy micro kit, Qiagen). hSef levels were evaluated using the DDCt comparative analysis method taking into account the amount of GAPDH in each sample (ABI technical bulletin 2). The values shown are therefore the total amount of endogenous hSef in each sample corrected for loading. The use of all tissue and patient data was in accordance with approval granted by the local hospital's ethics committee. A P-value of less than 0.05 was taken as statistically significant. (GG-Gleason grade) (*P ¼ 0.001 GG4 and 5 compared to benign tissue).
Loss of Sef in prostate cancer S Darby et al but in only 34% (10/29) of Gleason sum 8-10 cancer biopsies (P ¼ 0.004). Within areas of cancer, benign glands frequently demonstrated positive signals for hSef whereas adjacent malignant glands did not (Figure 3f ). hSef expression was not associated with the clinical stage of the disease at presentation (P ¼ 0.1). hSef expression was also not associated with the hormone responsive status of the cancer consistent with our in vitro findings in cell lines (P ¼ 0.4). To further validate our data from in situ hybridization, mRNA was obtained by laser capture microdissection (LCM) from a prospective cohort of five benign and nine malignant prostates. qPCR demonstrated that the highest levels of hSef were present in benign microdissected glands. In comparison, higher Gleason grades of malignant glands expressed progressively lower levels of hSef transcript consistent with our in situ hybridization data (P ¼ 0.001) (Figure 3g ). Yang et al. (2003) studying hSef mRNA levels in breast cancer tissue similarly observed uniform expression in well-differentiated tumours but less consistent and even absent expression in moderate and poorly differentiated tumours. Our in vitro studies have suggested that low endogenous levels of hSef are associated with a more invasive cell phenotype. Fifty primary prostate cancers were informative regarding the presence or absence of bone metastasis at presentation. Among these cancers, hSef expression was observed in only 18% (2/11) of malignant tumours with known bone metastasis at presentation. In contrast, 69% (27/39) of biopsies from non-metastatic tumours expressed hSef (P ¼ 0.004). These results suggest that reduced epithelial hSef expression is associated with aggressive clinical prostate cancer; high-grade disease and the presence of metastasis.
We had observed that FGF8 stimulation is capable of driving in vitro migration and invasion and that downregulation of hSef significantly enhanced this effect. We investigated if this combination of events occurred in clinical cancers. FGF8 (isoform b) protein has been previously characterized in a subgroup of the current clinical biopsies namely: 10 benign and 48 prostate cancer biopsies (Gnanapragasam et al., 2003) . In these samples, FGF8 was not detected in any of the benign biopsies (Table 1) . Overall, similar numbers of cancers appeared to express hSef and FGF8. When analysed by grade, however, only 38% (10/26) of Gleason sum 4-7 prostate cancers expressed FGF8 while 69% (18/26) of cases expressed hSef. In this grade range, 80% (8/10) of cancers that were FGF8 positive were also positive for hSef. Among Gleason sum 8-10 cancers, 86% (19/22) of cases expressed FGF8 while only 31% (7/22) expressed hSef (Table 1) . In this higher grade range, only 31% (6/19) of cancers that were FGF8 positive were also positive for hSef. Thirty-nine cases in this subgroup were informative of the presence or absence of bone metastasis at presentation. FGF8 expression was observed in 100% (8/8) of metastatic tumours and 45% (14/31) of non-metastatic tumours (P ¼ 0.005) ( Table 1) . hSef was expressed in 12% (1/8) of metastatic tumours and 64% (20/31) of non-metastatic tumours (P ¼ 0.009). Positive FGF8b expression but a loss of hSef was observed in 88% (7/8) of metastatic tumours. In contrast, metastasis was evident in only 10% (1/10) of tumours, which expressed both FGF8 and hSef (Po0.001). The numbers in this analysis are small and we interpret these results with caution. Nevertheless, these findings are consistent with our in vitro data and raise the possibility that FGF8 stimulation alone may not be sufficient to drive tumorigenesis. A loss of the intracellular regulatory mechanism may also play a part in enhancing the mitogenic and metastatic effects of growth factors. The study of tissue from metastatic sites for both hSef and FGF8 expression would be of particular value. In this regard, Dorkin et al. (2000) have previously shown high levels of FGF8 in metastatic prostate tissue to bone. A limitation of the present study is that we were unable to compare hSef protein levels with FGF8 owing to the lack of a suitable antibody. The correlation of the in vitro and clinical findings however would suggest that it is unlikely that the low mRNA levels observed are offset by increased translation or decreased hSef protein degradation.
Besides FGF8, other FGF ligand-receptor systems are known to be mitogenic in prostate cancer (Kwabi-Addo (Giri et al., 1999; Kwabi-Addo et al., 2004) . In vitro studies have demonstrated that Sef is capable of inhibiting FGFR1 phosphorylation and subsequent downstream signalling (Kovalenko et al., 2003) . In keeping with this, we observed that hSef downregulation significantly enhanced FGF2 stimulation of prostate cancer cells. It is reasonable to postulate therefore, that the loss of hSef expression might result in unattenuated FGF signalling capable of driving prostate cancer progression and metastasis. The in vitro findings in this study would support this notion and raise the possibility that in aggressive cancers, overexpression of mitogenic FGFs may occur in parallel with the loss of hSef. In support of this hypothesis, we observed that high grade and metastatic cancers expressed increasing amounts of FGF8 but reduced expression of hSef. Besides FGFs, Sef has also been implicated as a regulator of both nerve growth factor and epidermal growth factor signalling (Xiong et al., 2003; Torii et al., 2004) . Overexpression of Sef has also been shown to induce apoptosis through the activation of JNK (Yang et al., 2004) . More recently, Sef has been implicated in the regulation of Gbx2, itself a key modulator of IL6, a potent mitogen in androgenindependent prostate cancer (Gao et al., 2000; Lin et al., 2005) . These data point to a multifunctional role for Sef in cell signalling and homeostasis.
In conclusion, this study shows first evidence that hSef is downregulated in advanced prostate cancer. Our results raise the possibility that hSef might act as a tumour suppressor gene and its loss in the cancer cell may be associated with an enhanced response to FGF stimulation and a more metastatic phenotype. Future work will be directed at validating our findings in a larger cohort of cancers, confirming our transcript findings at the protein level, studying the mechanism of hSef downregulation and the role of hSef in cancer cell signalling with particular respect to its value as a therapeutic target in prostate cancer.
